News | Cath Lab | March 04, 2016

GlobalData: Stenting Viable Alternative to Surgery in Carotid Artery Stenosis

Opposing procedures show similar rates of adverse events and restenosis in CREST trial

CREST trial results, New England Journal of Medicine, stenting, endarterectomy, carotid artery stenosis

March 4, 2016 — Recent results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) are evidence that stenting will continue to remain competitive with surgical treatment, said an analyst with research and consulting firm GlobalData. CREST data has shown patients with severe carotid artery stenosis suffered similar rates of adverse events in both stenting and endarterectomy procedures.

The 10-year findings of the trial, published by the New England Journal of Medicine, showed adverse event rates of 11.8 percent in stenting and 9.9 percent in endarterectomy groups, with no significant difference in restenosis rates. In this way, both procedures exhibit similar long-term, post-procedural safety and efficacy profiles.

Premdharan Meyyan, GlobalData's analyst covering medical devices, states that in order for stenting to experience increased uptake, developers should prioritize improving solutions for embolic protection to minimize periprocedural stroke risk.

Meyyan said: “Carotid stenting systems with flow reversal and integrated embolic protection have potential to address the challenges with the current generation of products. GlobalData expects there will be an increased demand for these systems in coming years.

“Indeed, major peripheral vascular players that have developed and launched proximal embolic protection systems that incorporate flow reversal or arrest, with high rates of technical success, include Medtronic with its MoMa Ultra, and W.L Gore with its Gore Flow Reversal System.”

The analyst added that mesh-covered stents are also emerging as a potential solution to the periprocedural stroke rate. InspireMD has developed the CE-marked CGuard nitinol stent, which utilizes a polyethylene terephthalate mesh to provide continuous embolic protection, showing 100 percent procedural success and no major adverse events at the 30-day mark. 

Meyyan concluded: “These new technologies are promising, and show that opportunities continue to be available for companies to devise carotid artery stenting systems.

“Despite stenting’s stable reputation following the CREST trial results, the outcome from the CREST-2 trial, which compares clinical outcomes of surgery, stenting and medical therapy, will be pivotal in determining the future direction of carotid artery disease management.”

For more information: www.globaldata.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major